Cargando…

Role of β3-adrenergic receptors in the action of a tumour lipid mobilizing factor

Induction of lipolysis in murine white adipocytes, and stimulation of adenylate cyclase in adipocyte plasma membranes, by a tumour-produced lipid mobilizing factor, was attenuated by low concentrations (10(−7)–10(−5) M) of the specific β3-adrenoceptor antagonist SR59230A. Lipid mobilizing factor (25...

Descripción completa

Detalles Bibliográficos
Autores principales:	Russell, S T, Hirai, K, Tisdale, M J
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2002
Materias:	Experimental Therapeutics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2375201/ https://www.ncbi.nlm.nih.gov/pubmed/11875710 http://dx.doi.org/10.1038/sj.bjc.6600086

Ejemplares similares

Effect of a tumour-derived lipid-mobilising factor on glucose and lipid metabolism in vivo
por: Russell, S T, et al.
Publicado: (2002)

Role of lipid-mobilising factor (LMF) in protecting tumour cells from oxidative damage
por: Sanders, P M, et al.
Publicado: (2004)

Expression of uncoupling proteins-1, -2 and -3 mRNA is induced by an adenocarcinoma-derived lipid-mobilizing factor
por: Bing, C, et al.
Publicado: (2002)

Role of protein kinase C and NF-κB in proteolysis-inducing factor-induced proteasome expression in C(2)C(12) myotubes
por: Smith, H J, et al.
Publicado: (2004)

Induction of proteasome expression in skeletal muscle is attenuated by inhibitors of NF-κB activation
por: Wyke, S M, et al.
Publicado: (2004)

Increased expression of the ubiquitin – proteasome pathway in murine myotubes by proteolysis-inducing factor (PIF) is associated with activation of the transcription factor NF-κB
por: Whitehouse, A S, et al.
Publicado: (2003)

The role of zinc in the anti-tumour and anti-cachectic activity of D-myo-inositol 1,2,6-triphosphate
por: Russell, S T, et al.
Publicado: (2010)

Signal transduction pathways involved in proteolysis-inducing factor induced proteasome expression in murine myotubes
por: Smith, H J, et al.
Publicado: (2003)

A novel approach in the treatment of neuroendocrine gastrointestinal tumours. Targeting the epidermal growth factor receptor by gefitinib (ZD1839)
por: Höpfner, M, et al.
Publicado: (2003)

The role of glucocorticoids in the induction of zinc-α(2)-glycoprotein expression in adipose tissue in cancer cachexia
por: Russell, S T, et al.
Publicado: (2005)

The anticancer drug mithramycin A sensitises tumour cells to apoptosis induced by tumour necrosis factor (TNF)
por: Duverger, V, et al.
Publicado: (2004)

Development of an in-vitro model system to investigate the mechanism of muscle protein catabolism induced by proteolysis-inducing factor
por: Gomes-Marcondes, M C C, et al.
Publicado: (2002)

Adipose atrophy in cancer cachexia: morphologic and molecular analysis of adipose tissue in tumour-bearing mice
por: Bing, C, et al.
Publicado: (2006)

Functional identity of receptors for proteolysis-inducing factor on human and murine skeletal muscle
por: Mirza, K A, et al.
Publicado: (2014)

Induction of protein catabolism in myotubes by 15(S)-hydroxyeicosatetraenoic acid through increased expression of the ubiquitin–proteasome pathway
por: Whitehouse, A S, et al.
Publicado: (2003)

Influence of epidermal growth factor receptor (EGFR), p53 and intrinsic MAP kinase pathway status of tumour cells on the antiproliferative effect of ZD1839 (‘Iressa’)
por: Magné, N, et al.
Publicado: (2002)

Effect of eicosapentaenoic acid, protein and amino acids on protein synthesis and degradation in skeletal muscle of cachectic mice
por: Smith, H J, et al.
Publicado: (2004)

Attenuation of muscle atrophy by an N-terminal peptide of the receptor for proteolysis-inducing factor (PIF)
por: Mirza, K A, et al.
Publicado: (2011)

Superantigen reactive Vβ6(+) T cells induce perforin/granzyme B mediated caspase-independent apoptosis in tumour cells
por: Müerköster, S, et al.
Publicado: (2002)

17β-Oestradiol treatment modulates nitric oxide synthase activity in MDA231 tumour with implications on growth and radiation response
por: Chinje, E C, et al.
Publicado: (2002)

Angiotensin II directly induces muscle protein catabolism through the ubiquitin–proteasome proteolytic pathway and may play a role in cancer cachexia
por: Sanders, P M, et al.
Publicado: (2005)

Improved radiotracing of oxytocin receptor-expressing tumours using the new [(111)In]-DOTA-Lys(8)-deamino-vasotocin analogue
por: Chini, B, et al.
Publicado: (2003)

Antitumour efficacy of VEGFR2 tyrosine kinase inhibitor correlates with expression of VEGF and its receptor VEGFR2 in tumour models
por: Dev, I K, et al.
Publicado: (2004)

Expression pattern of the urokinase-plasminogen activator system in rat DS-sarcoma: Role of oxygenation status and tumour size
por: Weinmann, M, et al.
Publicado: (2002)

Effect of a tumour-produced lipid-mobilizing factor on protein synthesis and degradation
por: Islam-Ali, B S, et al.
Publicado: (2001)

Melanoma cell migration is upregulated by tumour necrosis factor-α and suppressed by α-melanocyte-stimulating hormone
por: Zhu, N, et al.
Publicado: (2004)

Invasion and MMP expression profile in desmoid tumours
por: Denys, H, et al.
Publicado: (2004)

Potentiation of ionising radiation by targeting tumour necrosis factor alpha using a bispecific antibody in human pancreatic cancer
por: Azria, D, et al.
Publicado: (2003)

IL-4 receptors on human medulloblastoma tumours serve as a sensitive target for a circular permuted IL-4-Pseudomonas exotoxin fusion protein
por: Joshi, B H, et al.
Publicado: (2002)

Relationship between tumour endothelial cell apoptosis and tumour blood flow shutdown following treatment with the antivascular agent DMXAA in mice
por: Ching, L-M, et al.
Publicado: (2004)

A novel hypoxia-dependent 2-nitroimidazole KIN-841 inhibits tumour-specific angiogenesis by blocking production of angiogenic factors
por: Shimamura, M, et al.
Publicado: (2003)

Dimethylarginine dimethylaminohydrolase I enhances tumour growth and angiogenesis
por: Kostourou, V, et al.
Publicado: (2002)

Secreted and tumour targeted human carboxylesterase for activation of irinotecan
por: Oosterhoff, D, et al.
Publicado: (2002)

Induction of tumour-specific CD8(+) cytotoxic T lymphocytes by tumour lysate-pulsed autologous dendritic cells in patients with uterine serous papillary cancer
por: Santin, A D, et al.
Publicado: (2002)

Gefitinib (‘Iressa’, ZD1839) inhibits the growth response of bladder tumour cell lines to epidermal growth factor and induces TIMP2
por: Nutt, J E, et al.
Publicado: (2004)

Zonal image analysis of tumour vascular perfusion, hypoxia, and necrosis
por: Fenton, B M, et al.
Publicado: (2002)

Stabilization of breast cancer xenograft tumour neovasculature by angiopoietin-1
por: Tian, S, et al.
Publicado: (2002)

Thiram inhibits angiogenesis and slows the development of experimental tumours in mice
por: Marikovsky, M
Publicado: (2002)

Effect of manipulation of primary tumour vascularity on metastasis in an adenocarcinoma model
por: Davies, M M, et al.
Publicado: (2002)

Arginine deprivation, growth inhibition and tumour cell death: 3. Deficient utilisation of citrulline by malignant cells
por: Wheatley, D N, et al.
Publicado: (2003)

Cannot write session to /tmp/vufind_sessions/sess_9imsll250v28t4gnm74s3lalkq